This week in Other Barks & Bites: The USPTO is postponing until January 2023 the filing fee for patent applications not filed in DOCX format; a recent Global Value of Music Copyright report finds that worldwide copyright value for music increased to $32.5 billion USD; B.E. Tech seeks mandamus relief at Federal Circuit, raising several constitutionality issues with inter partes review proceedings at the PTAB; Ford and GM make moves toward entering chip manufacturing industry; Ireland adopts EU Copyright Directive five months after the EU’s deadline; Jim Olive Photography files petition for cert over Takings Clause claim on state copyright infringement; the Federal Circuit remands a case to the TTAB to reconsider claims that Italian hardware maker Galperti made fraudulent representations on exclusive use of its trademark; former USPTO Directors Kappos and Iancu and former Commerce Secretary Locke blast U.S. support of TRIPS waiver as “strategic folly;” and the USPTO issues a final rule implemented the provisions of the Trademark Modernization Act, including new reexamination proceedings for challenging fraudulent marks.
Patent
- Enablement
- Fee Shifting
- Litigation
- This Week in Washington IP: IPWatchdog Event to Review the State of the PTAB; US Inventor Protests in D.C.; and the House Considers Supply Chain Challenges
- SCOTUS Sustains Blow to Patent Prosecution Practice in Denying Juno v. Kite Rehearing
- Opinion: Restoring The Road Less Traveled – American Invention at a Crossroad
- An Alternative to Claim Mirroring in Initial Patent Application Filing
- Bristol Myers Says AstraZeneca’s Imjudo Infringes Yervoy Patent
Recent Posts
- This Week in Washington IP: IPWatchdog Event to Review the State of the PTAB; US Inventor Protests in D.C.; and the House Considers Supply Chain Challenges
- SCOTUS Sustains Blow to Patent Prosecution Practice in Denying Juno v. Kite Rehearing
- Opinion: Restoring The Road Less Traveled – American Invention at a Crossroad
- An Alternative to Claim Mirroring in Initial Patent Application Filing
- Bristol Myers Says AstraZeneca’s Imjudo Infringes Yervoy Patent